Product image of Granisetron Beta (Granisetron) supplied by GNH India

Granisetron Beta

Active Ingredient:
Granisetron
Origin:
EU

Granisetron Beta (Granisetron)

Granisetron Beta is a prescription medication that contains the active ingredient granisetron. It is supplied as an oral product, though specific dosage form and strength are not disclosed. Classified as a 5-HT3 receptor antagonist, it belongs to the antiemetic therapeutic class and is marketed within the European Union.

Manufacturer / TM Owner

Betapharm Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Beta is indicated for the prevention of nausea and vomiting associated with specific medical procedures and treatments. It is commonly used in clinical practice for the following purposes:

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV)
  • Prevention of postoperative nausea and vomiting (PONV)
  • Management of nausea related to radiation therapy
  • Adjunct therapy for patients at high risk of emesis during surgical procedures
  • Supportive care in patients receiving highly emetogenic chemotherapy regimens

Side Effects

Granisetron Beta may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common

  • Headache
  • Constipation
  • Diarrhea
  • Fatigue
  • Dizziness
  • Flushing

Serious

  • Severe allergic reaction (anaphylaxis)
  • Cardiac arrhythmias
  • Prolonged QT interval
  • Severe hypotension
  • Serotonin syndrome (when combined with other serotonergic agents)

Precautions & Warnings

Before starting Granisetron Beta, certain precautions should be considered to ensure safe use. Patients and healthcare providers should be aware of the following:

  • Assess cardiac history, especially for QT prolongation risk
  • Review any known hypersensitivity to granisetron or similar compounds
  • Use cautiously in patients with electrolyte imbalances (e.g., low potassium or magnesium)
  • Monitor for signs of severe constipation or bowel obstruction
  • Consider renal or hepatic impairment when evaluating dosing needs
  • Discuss pregnancy and breastfeeding status with a healthcare professional, as safety data are limited

Avoid Interactions

Granisetron Beta can interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects.

Avoid

  • Other 5‑HT3 antagonists (duplicate therapy)
  • Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics)
  • Strong CYP3A4 inhibitors that may increase granisetron levels

Use with caution

  • Serotonergic agents (e.g., SSRIs, SNRIs, tramadol) due to serotonin syndrome risk
  • Medications that affect electrolyte balance (e.g., diuretics)
  • Anticholinergic drugs that may exacerbate constipation
  • Anesthetic agents used during surgery, as they may influence nausea control

Frequently Asked Questions

Granisetron Beta is a prescription antiemetic that belongs to the 5‑HT3 receptor antagonist class and is taken orally.

It is used to prevent nausea and vomiting caused by chemotherapy and by surgical procedures (post‑operative nausea and vomiting).

Granisetron blocks serotonin 5‑HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, interrupting the signaling pathway that triggers emesis.

Concurrent use with another 5‑HT3 antagonist is generally avoided to prevent duplicate therapy; other anti‑nausea agents may be used under medical supervision.

Common side effects include headache, constipation, diarrhea, fatigue, dizziness, and flushing.

Serious risks, though rare, can include severe allergic reactions, cardiac arrhythmias, prolonged QT interval, severe hypotension, and serotonin syndrome when combined with serotonergic drugs.

Patients with a history of cardiac arrhythmias or QT prolongation should discuss use with their healthcare provider, as caution is advised.

Safety data for use during pregnancy are limited; pregnant or breastfeeding women should consult their physician before using the medication.

Avoid other 5‑HT3 antagonists, strong CYP3A4 inhibitors, and drugs known to significantly prolong the QT interval.

Store the medication at room temperature, away from moisture and heat, and keep it out of reach of children.

Yes, constipation is a common side effect; patients should monitor bowel movements and report severe or persistent constipation to a healthcare professional.

If a dose is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose; do not double the dose. Consult a pharmacist or physician for specific guidance.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT